Maintenance therapy in multiple myeloma (Q36754178)

16 August 2017

1 reference

title

Maintenance therapy in multiple myeloma (English)

1 reference

16 August 2017

Mihelic R

1

1 reference

PubMed ID

17344913

16 August 2017

Kaufman JL

series ordinal

2

1 reference

PubMed ID

17344913

16 August 2017

Lonial S

series ordinal

3

1 reference

16 August 2017

8 March 2007

1 reference

16 August 2017

1 reference

16 August 2017

21

1 reference

16 August 2017

6

1 reference

16 August 2017

1150-1157

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404633

16 August 2017

0 references

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

Advances in biology of multiple myeloma: clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

Interferon therapy in myelomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

Interferon-alpha as maintenance therapy in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

Response rate and survival in myeloma patients receiving prednisone alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

Treatment of plasma cell dyscrasias with thalidomide and its derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

Thalidomide and dexamethasone for resistant multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

Thalidomide and hematopoietic-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

Signalling and survival pathways in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

7 January 2021

Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

7 January 2021

Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

7 January 2021

A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

7 January 2021

MRC trial of alpha2b-interferon maintenance therapy in first plateau phase of multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

7 January 2021

Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

7 January 2021

Randomized trial of alpha-interferon or dexamethasone as maintenance treatment for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

7 January 2021

Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

7 January 2021

Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

7 January 2021

High-dose glucocorticoid treatment of resistant myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

7 January 2021

High-dose dexamethasone for refractory or relapsing multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

7 January 2021

Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

7 January 2021

Thalidomide in the treatment of relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

7 January 2021

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404633

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404633

1 reference

16 August 2017

1 reference

PubMed ID

17344913